Nutrition, Metabolism & Cardiovascular Diseases
Volume 19, Issue 7 , Pages 481-490 , September 2009

Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment

  • D. Baldassarre

      Affiliations

    • Monzino Cardiology Center IRCCS, via Parea 4, 20138 Milan, Italy
    • Department of Pharmacological Sciences, Milan University, via Balzaretti 9, 20133 Milan, Italy
    • ,
  • B. Porta

      Affiliations

    • Department of Clinical Sciences, L. Sacco Hospital, Milan University, via G.B. Grassi 74, 20157 Milan, Italy
    • ,
  • M. Camera

      Affiliations

    • Monzino Cardiology Center IRCCS, via Parea 4, 20138 Milan, Italy
    • Department of Pharmacological Sciences, Milan University, via Balzaretti 9, 20133 Milan, Italy
    • ,
  • M. Amato

      Affiliations

    • Monzino Cardiology Center IRCCS, via Parea 4, 20138 Milan, Italy
    • ,
  • M. Arquati

      Affiliations

    • Department of Clinical Sciences, L. Sacco Hospital, Milan University, via G.B. Grassi 74, 20157 Milan, Italy
    • ,
  • B. Brusoni

      Affiliations

    • Division of Cardiology, Fatebenefratelli Hospital, C.so di Porta Nuova 23, 20121 Milan, Italy
    • ,
  • C. Fiorentini

      Affiliations

    • Monzino Cardiology Center IRCCS, via Parea 4, 20138 Milan, Italy
    • Division of Cardiology, San Paolo Hospital, via Di Rudinì 8, Milan University, 20142 Milan, Italy
    • ,
  • P. Montorsi

      Affiliations

    • Institute of Cardiology, Monzino Cardiology Center IRCCS, via Parea 4, 20138 Milan, Italy
    • ,
  • S. Romano

      Affiliations

    • Division of Cardiology, Ospedale Maggiore IRCCS, via F. Sforza 28, 20122 Milan, Italy
    • ,
  • F. Veglia

      Affiliations

    • Monzino Cardiology Center IRCCS, via Parea 4, 20138 Milan, Italy
    • ,
  • E. Tremoli

      Affiliations

    • Monzino Cardiology Center IRCCS, via Parea 4, 20138 Milan, Italy
    • Department of Pharmacological Sciences, Milan University, via Balzaretti 9, 20133 Milan, Italy
    • ,
  • M. Cortellaro

      Affiliations

    • Department of Clinical Sciences, L. Sacco Hospital, Milan University, via G.B. Grassi 74, 20157 Milan, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 02 3904 2320; fax: +39 02 3904 2356.
    • ,
  • on behalf of the MIAMI Study Group

Received 11 June 2008 ,Revised 6 October 2008 ,Accepted 13 October 2008.

References 

  1. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282(24):2340–2346
  2. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. Circulation. 2004;109(21 Suppl. 1):II18–II26
  3. Porta B, Baldassarre D, Camera M, Amato M, Arquati M, Brusoni B, et al. E-selectin and TFPI are associated with carotid intima-media thickness in stable IHD patients: the baseline findings of the MIAMI study. Nutr Metab Cardiovasc Dis. 2008 May;18(4):320–328Epub 2007 Sep 21
  4. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357(9256):577–581
  5. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106(16):2055–2060
  6. Yu CM, Zhang Q, Lam L, Lin H, Kong SL, Chan W, et al. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart. 2007;93(8):933–939
  7. Shukla A, Sharma MK, Jain A, Goel PK. Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients—a controlled randomized trial. Indian Heart J. 2005;57(6):675–680
  8. Ozaki K, Kubo T, Imaki R, Shinagawa H, Fukaya H, Ohtaki K, et al. The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia. J Atheroscler Thromb. 2006;13(4):216–219
  9. Youssef F, Seifalian AM, Jagroop IA, Myint F, Baker D, Mikhailidis DP, et al. The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg. 2002;23(4):358–364
  10. Sugiyama M, Ohashi M, Takase H, Sato K, Ueda R, Dohi Y. Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels. 2005;20(4):133–136
  11. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–1718
  12. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–1504
  13. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108(13):1560–1566
  14. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–28
  15. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–1158
  16. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–696
  17. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22
  18. Cortellaro M, Cofrancesco E, Arbustini E, Rossi F, Negri A, Tremoli E, et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost. 2002;88(1):41–47
  19. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993;118(12):956–963
  20. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999;398(6729):718–723
  21. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90(3):251–262
  22. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003;170(2):191–203
  23. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30years. Thromb Haemost. 2006;95(1):49–55
  24. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004;110(4):386–391
  25. Hansen JB, Huseby KR, Huseby NE, Sandset PM, Hanssen TA, Nordoy A. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscler Thromb Vasc Biol. 1995;15(7):879–885
  26. Nordoy A, Bonaa KH, Sandset PM, Hansen JB, Nilsen H. Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. Arterioscler Thromb Vasc Biol. 2000;20(1):259–265
  27. Morishita E, Asakura H, Saito M, Yamazaki M, Ontachi Y, Mizutani T, et al. Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients. Atherosclerosis. 2001;154(1):203–212
  28. Sebestjen M, Keber I, Zegura B, Simcic S, Bozic M, Fressart MM, et al. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb Haemost. 2004;92(5):1129–1135
  29. Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordoy A. Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb. 1994;14(2):223–229
  30. Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis. 1991;2(6):713–721
  31. Riesen WF, Engler H, Risch M, Korte W, Noseda G. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J. 2002;23(10):794–799
  32. Chan DC, Watts GF, Barrett PH, Beilin LJ, Mori TA. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem. 2002;48(6 Pt 1):877–883
  33. Costa A, Casamitjana R, Casals E, Alvarez L, Morales J, Masramon X, et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet Med. 2003;20(9):743–745
  34. van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis. 2003;166(1):129–135
  35. Yamada S, Yanagawa T, Sasamoto K, Araki A, Miyao M, Yamanouchi T. Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients. Metabolism. 2006;55(1):67–71
  36. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107(19):2409–2415
  37. Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Taylor AJ. Effect of atorvastatin and pravastatin on serum C-reactive protein. Am Heart J. 2003;145(2):e8
  38. Ordulu E, Erdogan O. Early effects of low versus high dose atorvastatin treatment on coagulation and inflammation parameters in patients with acute coronary syndromes. Int J Cardiol. 2007;
  39. Kinlay S, Timms T, Clark M, Karam C, Bilodeau T, Ridker PM, et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol. 2002;89(10):1205–1207
  40. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071–1080
  41. Alber HF, Frick M, Sussenbacher A, Dorler J, Dichtl W, Stocker EM, et al. Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease. Wien Med Wochenschr. 2007;157(3-4):73–78
  42. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103(15):1933–1935
  43. van Wissen S, Trip MD, Smilde TJ, de Graaf J, Stalenhoef AF, Kastelein JJ. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis. 2002;165(2):361–366
  44. Ascer E, Bertolami MC, Venturinelli ML, Buccheri V, Souza J, Nicolau JC, et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis. 2004;177(1):161–166
  45. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352(1):29–38
  46. Blanco-Colio LM, Martin-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, et al. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arterioscler Thromb Vasc Biol. 2007;27(1):168–174
  47. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol. 2007;49(20):2003–2009
  48. Cohen MC, Cohen S. Cytokine function: a study in biologic diversity. Am J Clin Pathol. 1996;105(5):589–598
  49. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998;128(2):127–137
  50. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448–454

☆ This work was partially supported by a grant from Pfizer-Italia, Rome, Italy.

PII: S0939-4753(08)00206-8

doi: 10.1016/j.numecd.2008.10.003

Nutrition, Metabolism & Cardiovascular Diseases
Volume 19, Issue 7 , Pages 481-490 , September 2009

Article Tools

* Image Usage & Resolution